NASDAQ
Adaptimmune Therapeutics plc (ADAP) has a free cash flow growth of 47.66% as of Friday, May 29, 2026. This represents a 833.83% increase compared to its 12-month average of -6.49%. Free cash flow growth tracks the year-over-year percentage change in cash generated after capital expenditures.
No price data available for this timeframe.